



## NETWORK GUIDELINE

|                      |   |
|----------------------|---|
| <b>Guideline:</b>    | <b>Management of Seizures in a Newborn (South Hub)</b>            |
| <b>Version:</b>      | <b>1</b>  |
| <b>Date:</b>         | <b>October 2020</b>   |
| <b>Review Date:</b>  | <b>October 2023</b>   |
| <b>Approval:</b>     | <b>EMNODN Clinical Governance Group</b>                           |
| <b>Authors:</b>      | <b>Shin Tan, Nanis Hamed, Chantelle Tomlinson, Robin Miralles</b> |
| <b>Consultation:</b> | <b>EMNDON Clinical Governance Group</b>                           |
| <b>Distribution:</b> | <b>Neonatal Units in the EMNODN South Hub</b>                     |
| <b>Risk Managed:</b> | <b>How to manage seizures appropriately</b>                       |

**This document is a guideline. Its interpretation and application remains the responsibility of the individual clinician, particularly in view of its applicability across the different Trusts in the East Midlands Neonatal Operational Delivery Network – South Hub. Please also consult any local policy/guideline document where appropriate and if in doubt contact a senior colleague.**

**Caution is advised when using guidelines after a review date.**

## REVIEW AND AMENDMENT LOG

| Version | Type of Change | Date      | Description of Change |
|---------|----------------|-----------|-----------------------|
| 1       | New guideline  | July 2020 | -                     |

## **Abbreviations used in this guideline:**

|                    |  |
|--------------------|--|
| BE:                | Base excess  |
| CFM:               | Cerebral function monitoring                                 |
| CRP:               | C-reactive protein   |
| CT:                | Computed tomography  |
| EEG:               | Electroencephalogram   |
| aEEG:              | Amplitude-integrated electroencephalography                  |
| cEEG:              | Continuous electroencephalography                            |
| HIE:               | Hypoxic-ischaemic encephalopathy                             |
| HSV:               | Herpes simplex virus   |
| IEM:               | Inborn error of metabolism                                   |
| MRI:               | Magnetic resonance imaging                                   |
| PCR:               | Polymerase chain reaction                                    |
| SaO <sub>2</sub> : | Oxygen saturations   |
| TORCH:             | Toxoplasmosis, rubella, cytomegalovirus, herpes simplex, HIV |

## Contents

|                                   |    |
|-----------------------------------|----|
| 1. Introduction: .....            | 5  |
| 2. Aetiology: .....               | 5  |
| 3. Clinical Manifestations: ..... | 6  |
| 4. Diagnosis: .....               | 8  |
| 5. Investigations: .....          | 10 |
| 6. Monitoring of Seizures: .....  | 11 |
| 7. Treatment:.....                | 12 |
| 8. Outcomes and Prognosis: .....  | 14 |
| 9. Follow up:.....                | 14 |
| 10. References:.....              | 15 |

## Appendices

|   |    |
|---|----|
| Appendix 1 - Key general physical examination findings for newborns with suspected seizures ..... | 17 |
| Appendix 2 - Factors determining outcome in neonatal seizures.....                                | 18 |
| Appendix 3 - Inborn errors of metabolism manifesting with seizures .....                          | 19 |
| Appendix 4 - Seizures on aEEG and Corresponding cEEG .....  | 20 |
| Appendix 5 - Neonatal Seizure Chart.....  | 22 |

## 1. Introduction

Seizures are the most common and distinctive manifestation of neurological disturbance in the neonatal period and have the highest incidence within the first four weeks of life<sup>1</sup>. They pose a major risk for death or subsequent neurological disability and can independently cause adverse neurodevelopmental outcomes in high-risk neonates<sup>2</sup>. There are also possible harmful effects of anticonvulsants on the developing brain.

The estimated incidence is 1.5-5.5 per 1000 births in term newborns and 10-100/1000 in preterm infants<sup>3,4</sup>. Most seizures are acute symptomatic (85%), but a small number are associated with epileptic syndromes (15%)<sup>5</sup>.

## 2. Aetiology

A seizure is a stereotypic, paroxysmal spell of altered neurological function, due to abnormal electrical activity in the brain. Neonatal seizures are significant because they are rarely idiopathic (Table 1 for possible aetiologies). Prompt diagnosis of any underlying condition is important; some specific treatments and when applied early, may improve outcome.

**Table 1: Aetiology of Neonatal Seizures**

- **Hypoxic-ischaemia** (Prenatal, Perinatal, Postnatal)
- **Cerebrovascular disorders** (Perinatal arterial ischaemic stroke, intraventricular haemorrhage, haemorrhagic parenchymal infarction, subarachnoid/subdural haemorrhage, Cerebral venous sinus thrombosis)
- **Intracranial infections** (Encephalitis, meningitis, abscess)
- **Transient metabolic / electrolyte disturbances** (hypoglycaemia, hypocalcaemia/hypomagnesaemia, hypernatraemia/ hyponatraemia)
- **Maternal drug withdrawal** (Sedatives, alcohol, opiates, barbiturates)
- **Inborn errors of metabolism** (IEM) (Appendix 3)
- **Malformations of cortical development**
- **Neurocutaneous syndromes** (tuberous sclerosis, incontinentia pigmenti, Sturge-Weber syndrome)
- **Neonatal epileptic syndromes / Epileptic encephalopathies** (Ohtahara syndrome, early myoclonic encephalopathy)
- **Idiopathic benign neonatal seizures** (Familial, non-familial)

In term infants, the most **common causes of seizures are HIE, ischaemic stroke and intracranial haemorrhage**<sup>6</sup>. In extremely preterm infants, the most common cause is intracranial haemorrhage; the presence of seizures is associated with adverse outcomes<sup>7,8</sup>. The timing of seizure onset may help to determine the possible aetiology<sup>9</sup>.

IEM are a rare cause of seizures but important to **consider in treatment resistant seizures**. The main mechanism of seizure generation is by accumulation of toxic metabolites, impaired neuronal function, associated brain malformation and vitamin or cofactor dependency<sup>10</sup>

### **3. Clinical Manifestations**

Four main types of seizures are recognised, and within each type seizures can be **unifocal, multifocal or generalised**. In the newborn, there is the unusual problem of electro-clinical dissociation<sup>11</sup>. Only around one third of term infants with electrical seizures have overt clinical signs. 70% of abnormal movements have no correlating EEG seizure activity<sup>12</sup>. See Table 2 below for EEG correlation and clinical association.

Neonatal EEG (electrical or electrical-clinical) seizures have a sudden change in the EEG, repetitive waveforms evolving in morphology and frequency and a duration of at least 10 seconds

**Table 2:** Types of seizures and their clinical manifestations<sup>11</sup>

| Type of seizure                                   | Clinical manifestations  | Correlation with EEG findings  | Clinical association  |
|---|--|--|---|
| <b>Clonic</b><br>(focal or multifocal)            | Repetitive rhythmic jerking, distinct from jittering.<br><br>Rapid twitch followed by slow relaxation.   | Usually EEG changes present –<br>Repetitive spikes   | Various, frequent in neonatal stroke and other structural brain abnormalities |
| <b>Myoclonic</b><br>(Rare - generalised or focal) | Rare. Resemble clonic movements but are quicker and appear more “jerky” with a predilection for flexor muscles.<br><br><b>Note: needs to be distinguished from sleep myoclonus which is benign</b>   | EEG often normal, although background EEG can be abnormal  | Metabolic or diffuse structural disorders                                     |
| <b>Tonic</b><br>(more common in preterm babies)   | Stiffening, decerebrate rigidity or decorticate posturing. Focal tonic head or eye turning.<br><br>Sustained contraction (flexion/extension).  | EEG variable May be prominent or completely absent or rhythmic delta activity  | Most often structural brain abnormalities, sometimes also metabolic disorders |
| <b>Subtle</b><br>(more common in term babies)     | Eye signs – eyelid fluttering, eye deviation, fixed open stare, blinking<br><br>Apnoea (not associated with bradycardia in seizures)<br><br>Body movements- cycling/pedalling, limb posturing<br><br>Oral signs- mouthing, chewing, lip smacking<br><br>Autonomic- vasomotor (tachycardia, unstable BP), pallor, apnoea, increased salivation/secretions | Sometimes flattening, may be normal, follow-up EEGs recommended<br><br>Often no EEG changes – most likely with ocular manifestations | Various, frequent in hypoxic-ischaemic encephalopathy                         |

## 4. Diagnosis

Neonatal seizures are a common neonatal emergency. Confirmation of seizures should initiate urgent and appropriate **clinical and laboratory evaluation** for aetiological cause. A full history and examination should be performed, together with urgent comprehensive biochemical tests for correctable metabolic disturbances (first line investigations).

### 4.1 History

#### Antenatal history:

- Routine anomaly scan findings
- Illness during pregnancy
- Maternal morbidities e.g. diabetes
- Frequency & character of movements in utero (classically, seizures in utero can mimic hiccoughs)
- Maternal drug use – prescribed or illicit
- History of infections (including genital herpes)

#### Perinatal and birth history:

- Prolonged rupture of membranes & risk factors for infection
- Eclampsia
- Labour and delivery complications (trauma, fetal distress)
- Evidence of intrapartum hypoxia:

#### Family history of seizures:

History of similar presentation and transient nature in siblings or parents would suggest Benign Familial Neonatal Convulsions. Some neuro-cutaneous disorders may be inherited. A family history of metabolic disorder should be considered especially if consanguineous marriage.

## 4.2 Age at Onset

| Time of onset     | Day 1  | Day 2 | Day 3  | Day 4   | Day 5 | Day 6 and beyond |
|-------------------|--|-------|--|---|-------|------------------|
| Seizure aetiology | Structural, developmental brain abnormalities<br>Intrauterine (congenital) infection<br>Pyridoxine dependent/pyridoxal phosphate responsive epilepsy |       |  |   |       |                  |
|                   | Perinatal asphyxia<br>Sepsis<br>Hypoglycaemia<br>Perinatal stroke<br>Maternal drug withdrawal<br>Periventricular haemorrhage<br>Perinatal trauma     |       |  |   |       |                  |
|                   |  |       | Hypoglycaemia<br>Benign familial neonatal convulsions<br>Hypocalcaemia   |   |       |                  |
|                   |  |       | Aminoacidopathies<br>Galactosaemia<br>Ketotic and non-ketotic hyperglycinaemia<br>Follic acid-responsive seizures<br>Glucose transporter type 1 deficiency<br>Ohtahara<br>Early myoclonic epilepsy |   |       |                  |
|                   |  |       |  | Benign neonatal seizures<br>Migrating partial seizures of infancy |       |                  |

**Figure 1:** Aetiology of seizures by predominant time of onset<sup>13,14</sup>

### 4.3 Description of seizure

- Type of seizure (as above)
- Frequency and duration
- Clear onset and offset
- Any provoking factors
- Relationship to sleep pattern
- Association with eye deviation or autonomic disturbance
- Document whether they are stopped or modified with posture or gentle restraint (unlikely seizure)

### 4.4 Examination

**See Appendix 1** for key findings in general physical examination for the newborn with suspected seizures.

Physical examination– complete systematic examination including the following:

- Head circumference
- Skin/cutaneous examination
- Ophthalmological examination (often 2<sup>nd</sup> line)
- Facial (or other) dysmorphism or congenital anomalies
- Neurological examination

## 5. Investigations

Investigations can be considered as **1<sup>st</sup> line** – to follow history and examination in the event of confirmed or highly suspected seizures (Table 3 below), **and 2<sup>nd</sup> line** – initiated in tertiary NICU after referral and discussion with on-call Neonatologist and/or paediatric neurologists.

**Table 3:** Investigations of seizures<sup>15</sup>

| <b>Evaluation</b>             | <b>First line investigations</b>   | <b>Second-line investigations</b>  |
|-------------------------------|--|--|
| Clinical                      | Complete history, general and neurological examination   | Dilated ophthalmologic exam<br>Pyridoxine/pyridoxal phosphate therapeutic trial  |
| Blood                         | Sodium (U&E), glucose, ionised calcium, magnesium, phosphate, LFT, blood gas (pH, bicarbonate, lactate), bilirubin<br><br>FBC, coagulation screen<br>CRP, blood culture, HSV PCR       | Carnitine, acylcarnitine, TFT, carbohydrate deficient transferrin, biotinidase enzyme activity, ammonia, lactate, Urate, pyruvate, amino acids, TORCH titres |
| Urine                         | Urine culture<br>Toxicology screen if appropriate (request maternal also)  | Reducing substances, sulfites, organic and amino acids, alpha amino adipic semialdehyde (AASA)   |
| Cerebrospinal fluid           | Paired (plasma and CSF) glucose<br>Cell counts and differential<br>Glucose and total protein<br>HSV PCR, Enterovirus PCR<br>Gram stain and culture<br>*Consider save sample for future | Lactate, amino acids, (CSF neurotransmitter profile in consultation with paediatric neurology)   |
| Neurophysiology/ neuroimaging | aEEG (CFM, if available)<br>EEG<br>Cranial ultrasound<br>Urgent CT scan if focal neurology and intracerebral bleed suspected<br>MRI (rarely acute)                                     | MR spectroscopy, angiography and venography  |

## **Neuroimaging**

Cranial ultrasound may identify large intracranial haemorrhages or significant congenital abnormalities. MRI may be helpful in diagnosis and prognosis<sup>16</sup>. Where intracranial **haemorrhage is suspected, CT scanning may be preferred** to MRI but should be discussed with the neonatal consultant and consultant radiologist before undertaking.

**Generally, unless there is a clear cause and prognosis, or scanning is specifically indicated earlier, MRI is recommended at 7-14 days. For seizures associated with HIE, MR imaging is recommended at Day 5<sup>17</sup>.**

## **6. Monitoring of Seizures**


### **6.1 Clinical**

Clinical suspicion of seizure as described previously in section 4.3 and recording them on a seizure chart (See Appendix 5).

### **6.2 Amplitude integrated EEG (aEEG; Cerebral Function Monitor CFM, if available on your local unit and if trained to use/interpret)**

aEEG should be commenced if seizure disorder is suspected in a term/ near term infant, particularly if at significant risk (e.g. following intrapartum hypoxia) and muscle relaxed. Interpretation in pre-term infants is challenging and use is therefore not recommended outside tertiary settings.

Most electrographic seizures on aEEG are characterized as an **abrupt, transient, sharp rise in the lower margin**, often accompanied by a **smaller rise in the upper margin**, with narrowing of the bandwidth<sup>18</sup> as shown below, for more examples please (See Appendix 4)



**Status epilepticus** on aEEG is depicted as frequent, recurrent seizures giving a saw tooth appearance. It is defined as **>30 minutes or >50% of the recording, or both**. Continuous seizure activity or brief inter-ictal periods between seizures can be mistaken as normal.

**Artefacts commonly mistaken for seizures** on aEEG include mechanical ventilation, arousal patterns, patient manipulation, sucking or chewing and electrode artefacts. Notation of **any intervention with baby should be recorded**. Reviewing the corresponding raw EEG is essential to confirm seizures seen on aEEG<sup>18</sup>.

### **6.1 EEG**

EEG is usually unhelpful in acute control of seizures (use aEEG if available on your local unit). A formal EEG may be useful in confirming seizure activity in the presence of subtle neurological signs and for assessing control in infants under heavy sedation.

## 7. Treatment:

There is no high level evidence on the threshold for starting treatment of seizures and is limited to expert opinion<sup>19,20</sup>. Due to the high frequency of EEG-only seizures, continuous aEEG or EEG monitoring should be commenced if seizures are suspected (if this is available on your local unit), ideally commenced before anticonvulsants are administered (unless the infant is cardiorespiratory compromised by the seizure). Many anticonvulsants will alter the background electrical activity making neurophysiological assessments challenging<sup>21</sup>. See **Figure 2 Treatment algorithm (EMNODN – South Hub)**.

### Firstly: Supportive management

- Airway, Breathing, Circulation
- Consider and treat any reversible underlying causes, for example:
- Is the blood glucose normal? Follow local guideline for treatment of hypoglycaemia.
- Is bacterial infection or meningitis likely? Follow local infection guideline.
- Is blood chemistry normal? Treat any significant electrolyte disturbance.

### Secondly: treat the seizures if:

- A single isolated seizure **lasts  $\geq 3$  mins** or  **$\geq 3$  seizures per hour**
- Treat seizures associated with cardiorespiratory compromise


If trained in using and interpreting aEEG (CFM), **you may consider** treating subclinical (electrical only) seizures on aEEG (CFM) to reduce seizure burden. This may be associated with better short term outcomes<sup>22,23</sup> but should anticonvulsants are not without significant potential adverse effects. **Treatment of subclinical seizures should therefore only occur after consultant level discussion.**

Escalating anti-seizure treatment should always be discussed with the tertiary Neonatal Consultant at each step or by a bespoke agreed plan.

### **Discontinuation of anticonvulsants:**

Most seizures in the neonatal period are Acute Symptomatic and seizure burden is finite; greatest soon after injury, hence anticonvulsant medication should be discontinued after the seizures have stopped and the neurological examination has normalised or is normalising<sup>24</sup>. If the seizures are suspected to be due to a neonatal epilepsy syndrome, this should be managed in conjunction with tertiary paediatric neurologists.

**Figure 2: Treatment algorithm for neonatal seizures (EMNODN – South Hub):**



### Vitamin-responsive epilepsies:

Investigations for vitamin-responsive epilepsies and a therapeutic trial of vitamins should be given for refractory neonatal seizures where no other cause has been identified in conjunction with tertiary paediatric neurologists. Pyridoxine **may cause apnoea or cerebral depression in those with pyridoxine dependant seizures**<sup>25</sup> **especially if they have received anticonvulsants**, therefore careful observation is required.

**Table 4:** Recommended doses for vitamin-responsive epilepsy in neonates<sup>25-27</sup>

| Drug                            | Dose   |
|---------------------------------|--|
| Biotin                          | 5mg orally/NGT twice a day, can increase up to 10mg twice a day  |
| Folinic acid (Calcium folinate) | 5mg orally/NGT twice a day   |
| Pyridoxine                      | 100mg intravenous trial dose repeated every 10 min to a max of 500mg<br><br>If positive, can be given orally 15mg/kg/day in divided doses to a maximum of 500mg) |
| Pyridoxal phosphate             | Surtees <sup>28</sup> : 10mg/kg/dose 2 hr apart orally as trial<br><br>Baxter: 50mg/kg/day in divided doses for 2 weeks  |

### 8. Outcomes and Prognosis:

There is a low risk of seizure recurrence after early discontinuation of anticonvulsant medication in the neonatal period. Seizures often signify babies at increased risk of dying (approximately 15% mortality) or surviving with neurological impairment, developmental delay or later epilepsy (approximately 30%). The strongest predictors of outcome remain the underlying cause of the seizure, together with the background electroencephalographic activity.

Prognosis should only be determined after careful consideration of all the available information following investigation of the underlying cause<sup>29</sup>.

### 9. Follow up:

Infants who develop seizures should be followed up and have a neurodevelopmental assessment performed (including two-year follow up). Other specialties may be involved, this is dependent on the underlying cause and response to treatment.

## 10. References:

1. Vasudevan C, Levene M. Epidemiology and aetiology of neonatal seizures. *Semin Fetal Neonatal Med.* 2013 Aug;18(4):185–91.
2. Clancy RR. Summary proceedings from the neurology group on neonatal seizures. *Pediatrics.* 2006 Mar;117(3 Pt 2):S23-27.
3. Ronen GM, Penney S, Andrews W. The epidemiology of clinical neonatal seizures in Newfoundland: a population-based study. *J Pediatr.* 1999 Jan;134(1):71–5.
4. Lanska MJ, Lanska DJ, Baumann RJ, Kryscio RJ. A population-based study of neonatal seizures in Fayette County, Kentucky. *Neurology.* 1995 Apr;45(4):724–32.
5. Shellhaas RA, Wusthoff CJ, Tsuchida TN, Glass HC, Chu CJ, Massey SL, et al. Profile of neonatal epilepsies: Characteristics of a prospective US cohort. *Neurology.* 2017 Aug 29;89(9):893–9.
6. Glass HC, Shellhaas RA, Wusthoff CJ, et al. Contemporary Profile of Seizures in Neonates: A Prospective Cohort Study. *J Pediatr.* 2016 Jul;174:98-103.e1.
7. Glass HC, Shellhaas RA, Tsuchida TN, Chang T, Wusthoff CJ, Chu CJ, et al. Seizures in Preterm Neonates: A Multicenter Observational Cohort Study. *Pediatr Neurol.* 2017 Jul;72:19–24.
8. Pisani F, Facini C, Pelosi A, Mazzotta S, Spagnoli C, Pavlidis E. Neonatal seizures in preterm newborns: A predictive model for outcome. *Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc.* 2016 Mar;20(2):243–51.
9. Neubauer D, Soltirovska-Salamon A, Osredkar D, Paro-Panjan D. Management of refractory neonatal seizures. *Res Rep Neonatol.* 2014 Feb 26;Volume 4:17.
10. Dulac O, Plecko B, Gataullina S, Wolf NI. Occasional seizures, epilepsy, and inborn errors of metabolism. *Lancet Neurol.* 2014 Jul;13(7):727–39.
11. Rennie JM. Neonatal seizures. *Eur J Pediatr.* 1997 Jan 1;156(2):83–7.
12. Murray DM, Boylan GB, Ali I, Ryan C a, Murphy BP, Connolly S. Defining the gap between electrographic seizure burden, clinical expression and staff recognition of neonatal seizures. *Arch Dis Child Fetal Neonatal Ed.* 2008 May;93(3):F187-91.
13. Hart AR, Pilling EL, Alix JJP. Neonatal seizures-part 2: Aetiology of acute symptomatic seizures, treatments and the neonatal epilepsy syndromes. *Arch Dis Child Educ Pract Ed.* 2015 Oct;100(5):226–32.
14. Appleton RE, Gibbs J. *Epilepsy in Childhood and Adolescence.* CRC Press;1998. 164 p.
15. Shellhaas RA. Clinical features, evaluation, and diagnosis of neonatal seizures [Internet]. Uptodate. 2016 [cited 2017 Nov 1]. Available from: <https://www.uptodate.com/contents/clinical-features-evaluation-and-diagnosis-of-neonatal-seizures>
16. Weeke LC, Van Rooij LGM, Toet MC, Groenendaal F, de Vries LS. Neuroimaging in neonatal seizures. *Epileptic Disord Int Epilepsy J Videotape.* 2015 Mar;17(1):1–11; quiz 11.
17. BAPM Framework for Practice: Fetal & Neonatal Brain Magnetic Resonance Imaging: Clinical Indications, Acquisitions and Reporting. 2016.

18. El-Dib M, Chang T, Tsuchida TN, Clancy RR. Amplitude-integrated electroencephalography in neonates. *Pediatr Neurol*. 2009 Nov;41(5):315–26.
19. Slaughter LA, Patel AD, Slaughter JL. Pharmacological treatment of neonatal seizures: a systematic review. *J Child Neurol*. 2013 Mar;28(3):351–64.
20. Evans DJ, Levene MI, Tsakmakis M. Anticonvulsants for preventing mortality and morbidity in full term newborns with perinatal asphyxia. *Cochrane Database Syst Rev Online*. 2007 Jan;(3):CD001240.
21. Austin T, O'Hare S. Diagnosis and management of neonatal seizures in the term infant. *East of England Neonatal ODN*;
22. van Rooij LGM, Toet MC, van Huffelen AC, Groenendaal F, Laan W, Zecic A, et al. Effect of treatment of subclinical neonatal seizures detected with aEEG: randomized, controlled trial. *Pediatrics*. 2010 Feb;125(2):e358-66.
23. Srinivasakumar P, Zempel J, Trivedi S, Wallendorf M, Rao R, Smith B, et al. Treating EEG Seizures in Hypoxic Ischemic Encephalopathy: A Randomized Controlled Trial. *Pediatrics*. 2015 Nov;136(5):e1302-9.
24. Wusthoff CJ, Kessler SK, Vossough A, Ichord R, Zelonis S, Halperin A, et al. Risk of Later Seizure After Perinatal Arterial Ischemic Stroke: A Prospective Cohort Study. *PEDIATRICS*. 2011 Jun 1;127(6):e1550–7.
25. Baxter P. Pyridoxine-dependent and pyridoxine-responsive seizures. *Dev Med Child Neurol*. 2001 Jun;43(6):416–20.
26. Hart AR, Pilling EL, Alix JJP. Neonatal seizures-part 2: Aetiology of acute symptomatic seizures, treatments and the neonatal epilepsy syndromes. *Arch Dis Child Educ Pract Ed*. 2015 Mar 30;100(5):226–32.
27. Gospe SM. Neonatal vitamin-responsive epileptic encephalopathies. *Chang Gung Med J*. 2010;33(1):1–12.
28. Surtees R, Wolf N. Treatable neonatal epilepsy. *Arch Dis Child*. 2007 Aug;92(8):659–61.
29. Crozier D, Brown V, Jayasinghe D, Deorukhkar A. Management of seizures in the newborn (E10). *Nottingham University Hospitals NHS Trust Guidelines*.; 2018.
30. Uria-Avellanal C, Marlow N, Rennie JM. Outcome following neonatal seizures. *Semin Fetal Neonatal Med*. 2013 Aug 1;18(4):224–32.
31. Hellstrom-Westas L, Rosen I, de Vries LS, Greisen G. Amplitude-integrated EEG Classification and Interpretation in Preterm and Term Infants. *Neoreviews*. 2006;7(2):e76-87.
32. Thoresen M, Hellström-Westas L, Liu X, de Vries LS. Effect of hypothermia on amplitude-integrated electroencephalogram in infants with asphyxia. *Pediatrics*. 2010 Jul;126(1):e131-9.
33. Seizures in the Neonatal. Greater Glasgow and Clyde neonatal guideline. <https://www.clinicalguidelines.scot.nhs.uk/ggc-paediatric-guidelines/ggc-guidelines/neonatology/seizures-in-the-neonate/>
34. Hart AR. Seizures (Neonatal). *Jessop Wing Neonatology Clinical Practice Guideline (Sheffield)*

## Appendix 1 - Key general physical examination findings for newborns with suspected seizures<sup>15</sup>

| Physical Examination          | Diagnostic considerations based on findings   |
|-------------------------------|---|
| Head circumference            | <ul style="list-style-type: none"> <li>• Macrocephaly- Hydrocephalus or hemimegalencephaly</li> <li>• Microcephaly- Congenital CNS infections (esp TORCH infections) or congenital CNS lesions</li> </ul>   |
| Skin/cutaneous examination    | <ul style="list-style-type: none"> <li>• Vesicular lesions – consider HSV infection</li> <li>• Vesicular lesions in a dermatomal pattern- Incontinentia pigmenti</li> <li>• Port wine stain of forehead/eyelid- consider Sturge-Weber syndrome and evaluate for glaucoma</li> <li>• Nevus or discoloration in a dermatomal or whorled pattern- developmental cerebral dysgenesis</li> <li>• “Blueberry muffin” skin appearance- congenital Rubella infection (or other TORCH infections)</li> <li>• Ash leaf macule- tuberous sclerosis</li> <li>• Cutis aplasia (lack of hair and skin in a localized area)- associated developmental cerebral dysgenesis</li> </ul> |
| Ophthalmological examination  | <ul style="list-style-type: none"> <li>• Hypoplastic optic nerves – cerebral dysgenesis (e.g. septo-optic dysplasia)</li> <li>• Chorioretinitis – congenital CNS infections</li> <li>• Abnormal retinal pigmentation- neuronal ceroid lipofuscinosis</li> <li>• Coloboma- agenesis of corpus callosum</li> <li>• Congenital cataract- congenital CNS infection (esp TORCH) or metabolic (storage) disorders</li> </ul>  |
| Facial (or other) dysmorphism | <ul style="list-style-type: none"> <li>• Hypotelorism, cleft lip/palate (mid-face abnormalities)- cerebral dysgenesis (e.g. holoprosencephaly)</li> <li>• Multiple congenital anomalies- chromosomal abnormalities (Trisomy syndromes, partial deletions/duplications)</li> </ul>   |
| Mental status                 | <ul style="list-style-type: none"> <li>• Irritable, jittery- neonatal encephalopathy (e.g. due to HIE, neonatal abstinence syndrome, pyridoxine dependant seizures)</li> <li>• Lethargy, decreased responsiveness- neonatal encephalopathy (e.g. due to HIE); severe systemic illness and/or infection (e.g. meningoencephalitis)</li> </ul>  |

## Appendix 2 - Factors determining outcome in neonatal seizures<sup>30</sup>

### Factors associated with poor outcomes are:

- Prematurity
- HIE
- Cerebral dysgenesis
- Central nervous system infection
- Severe IVH
- Severe abnormal EEG inter-ictal activity (isoelectric pattern, paroxysmal, burst-suppression and low-voltage background)
- Less strongly associated:
  - Severely abnormal neurological examination (less specific)
  - Severely abnormal neuroimaging
  - Early onset of seizures (within 24hrs; related to HIE in term babies)
  - Severity of seizures/presence of status epilepticus

### Factors associated with favourable outcomes are:


- Focal infarct ('stroke') on MRI
- Transient metabolic disturbance e.g. hypocalcaemia
- Normal inter-ictal EEG activity
- Normal early neurological examination
- Diagnosis of benign familial seizures
- Neonatal sleep myoclonus
- Clinical seizures with no EEG correlate
- Less strongly associated:
  - Normal/mild abnormality on neuroimaging
  - Late onset (>5 days; related to benign neonatal seizures)
  - Focal clonic seizures, likely related to focal structural lesion in the brain

### Appendix 3 - Inborn errors of metabolism manifesting with seizures<sup>10</sup>


A number of IEM may present in the neonatal period:

| <b>Mechanism of seizure generation</b>                      | <b>Aetiology</b>   |
|---|--|
| Energy deficiency   | Hypoglycaemia, glucose transporter-1 deficiency, respiratory chain deficiency, pyruvate dehydrogenase deficiency, Krebs cycle defects, creatine deficiencies   |
| Toxic effect  | Aminoacidopathies, organic acidurias, urea cycle defects, molybdenum cofactor deficiency, sulphite oxidase deficiency  |
| Impaired neuronal function                                  | Storage disorders  |
| Disturbance of neurotransmitter systems                     | Non-ketotic hyperglycinaemia, atypical phenylketonuria, gamma aminobutyric acid (GABA) transaminase deficiency, succinic semialdehyde dehydrogenase deficiency   |
| Associated brain malformations                              | Peroxisomal disorders (Zellweger syndrome), respiratory chain deficiency, pyruvate dehydrogenase deficiency, O-glycosylation defects (congenital muscular dystrophies)   |
| Vitamin or cofactor dependency, vitamin transporter defects | Biotinidase deficiency, pyridoxine-dependent and pyridoxal 5'-phosphate dependent epilepsy (folinic-acid-responsive seizures), thiamine transporter deficiency, Menkes' disease, folate transporter defect, dihydrofolate reductase deficiency |
| Miscellaneous   | Serine biosynthesis deficiency   |


## Appendix 4 - Seizures on aEEG and Corresponding cEEG



**4.1: a)** Three single seizures, each lasting for 2 to 4 minutes and appearing at 1- to 1.5-hour intervals on a discontinuous background. Twenty-five seconds of EEG corresponds with the first seizure. The left margin of the blue vertical bar in the aEEG corresponds with the displayed EEG.




**b)** Repetitive seizures with 10- to 35-minute intervals on a continuous background aEEG. The 12-second EEG display is from the seventh seizure (counting from left) with the blue vertical bar.




**c)** Status epilepticus (“saw-tooth pattern”) after perinatal asphyxia. Administration of midazolam (red arrow) results in temporary depression of seizures and background activity. The blue vertical bar in the aEEG corresponds with the 12 seconds of EEG.

d)



**d) This is not a seizure pattern!** High-frequency oscillation ventilation resulted in a very variable and raised minimum aEEG amplitude and clearly visible high-frequency interference in the EEG. The 25 seconds of EEG shows the aEEG at the blue vertical bar in this 4-hour aEEG recording. The discontinuous background in this extremely preterm infant is still possible to appreciate, but seizure activity, if present, probably would be missed. The risk of interference from mechanical ventilation on the aEEG is reduced if care is taken that electrodes are not pressed against bedding<sup>31</sup>.



4.2: Classifications of 5 example traces by using the pattern recognition method (right) and voltage method (left) to assess the aEEG background at 3 to 6 hours of age<sup>32</sup>.



